Brokers Offer Predictions for GPCR Q1 Earnings

Key Points

• Lifesci Capital estimates Structure Therapeutics will report a Q1 2027 loss of ($0.47) per share, with full-year 2027 earnings still expected to be negative at ($1.36) per share.
• Other analysts remain generally upbeat on the stock: the consensus rating is “Moderate Buy” with an average price target of $109.25, though opinions are mixed across firms.
• Structure Therapeutics most recently reported a quarterly EPS of ($0.35), beating estimates by $0.04, while the stock was trading at $39.10 versus a 12-month high of $94.90.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Stock analysts at Lifesci Capital issued their Q1 2027 earnings per share estimates for shares of Structure Therapeutics in a research report issued on Friday, May 8th. Lifesci Capital analyst P. Dolezal forecasts that the company will post earnings per share of ($0.47) for the quarter. The consensus estimate for Structure Therapeutics' current full-year earnings is ($1.36) per share. Lifesci Capital also issued estimates for Structure Therapeutics' Q2 2027 earnings at ($0.49) EPS and Q3 2027 earnings at ($0.53) EPS.

A number of other analysts also recently issued reports on the company. Leerink Partners reissued an "outperform" rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Wolfe Research initiated coverage on Structure Therapeutics in a research report on Thursday, March 26th. They set a "peer perform" rating for the company. Guggenheim raised their target price on Structure Therapeutics from $90.00 to $140.00 and gave the company a "buy" rating in a report on Tuesday, January 20th. Citizens Jmp lowered their target price on Structure Therapeutics from $120.00 to $113.00 and set a "market outperform" rating for the company in a report on Friday, February 27th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Structure Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $109.25.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $39.10 on Monday. The business has a 50-day moving average price of $51.87 and a 200 day moving average price of $56.12. The company has a market capitalization of $2.77 billion, a price-to-earnings ratio of -44.94 and a beta of -1.31. Structure Therapeutics has a 12-month low of $15.80 and a 12-month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.04.

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in GPCR. Morgan Stanley boosted its stake in shares of Structure Therapeutics by 261.4% in the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company's stock valued at $145,209,000 after buying an additional 1,510,093 shares during the period. Wellington Management Group LLP boosted its stake in shares of Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company's stock valued at $495,334,000 after buying an additional 1,432,797 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Structure Therapeutics by 477.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company's stock valued at $116,228,000 after buying an additional 1,381,745 shares during the period. Avoro Capital Advisors LLC boosted its stake in shares of Structure Therapeutics by 21.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company's stock valued at $455,939,000 after buying an additional 1,150,000 shares during the period. Finally, Capitolis Liquid Global Markets LLC purchased a new position in shares of Structure Therapeutics in the 4th quarter valued at about $61,086,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.